Children's Medicines

2017 ◽  

2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Grace Frimpong ◽  
Kwabena Ofori-Kwakye ◽  
Noble Kuntworbe ◽  
Kwame Ohene Buabeng ◽  
Yaa Asantewaa Osei ◽  
...  

The quality of 68 samples of 15 different essential children’s medicines sold in licensed medicine outlets in the Ashanti Region, Ghana, was evaluated. Thirty-two (47.1%) of the medicines were imported, mainly from India (65.6%) and the United Kingdom (28.1%), while 36 (52.9%) were locally manufactured. The quality of the medicines was assessed using content of active pharmaceutical ingredient (API), pH, and microbial limit tests, and the results were compared with pharmacopoeial standards. Twenty-six (38.2%) of the samples studied passed the official content of API test while 42 (61.8%) failed. Forty-nine (72.1%) of the samples were compliant with official specifications for pH while 19 (27.9%) were noncompliant. Sixty-six (97.1%) samples passed the microbial load and content test while 2 (2.9%) failed. Eighteen (26.5%) samples passed all the three quality evaluation tests, while one (1.5%) sample (CFX1) failed all the tests. All the amoxicillin suspensions tested passed the three evaluation tests. All the ciprofloxacin, cotrimoxazole, flucloxacillin, artemether-lumefantrine, multivitamin, and folic acid samples failed the content of API test and are substandard. The overall API failure rate for imported products (59.4%) was comparable to locally manufactured (63.9%) samples. The results highlight the poor quality of the children’s medicines studied and underscore the need for regular pharmacovigilance and surveillance systems to fight this menace.



PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e58303 ◽  
Author(s):  
Lisa V. Adams ◽  
Sienna R. Craig ◽  
Elia John Mmbaga ◽  
Helga Naburi ◽  
Timothy Lahey ◽  
...  


2007 ◽  
Vol 8 (3) ◽  
pp. 123-123
Author(s):  
Imti Choonara ◽  
Michael Rieder


2019 ◽  
Vol 4 (Suppl 9) ◽  
pp. e001306 ◽  
Author(s):  
Benson Droti ◽  
Kathryn Patricia O’Neill ◽  
Matthews Mathai ◽  
Delanyo Yao Tsidi Dovlo ◽  
Jane Robertson

BackgroundMost maternal and child deaths are preventable or treatable with proven, cost-effective interventions for infectious diseases and maternal and neonatal complications. In 2015 sub-Saharan Africa accounted for up to 66% of global maternal deaths and half of the under-five deaths. Access to essential medicines and commodities and trained healthcare workers to provide life-saving maternal, newborn and post-natal care are central to further reductions in maternal and child mortality.MethodsAvailable data for 24 priority medicines for women and children were extracted from WHO service availability and readiness assessments conducted between 2012 and 2015 for eight countries in sub-Saharan Africa. The mean availability of medicines in facilities stating they provide services for women or children and differences by facility type, ownership and location are reported.ResultsThe mean availability of 12 priority essential medicines for women ranged from 22% to 40% (median 33%; IQR 12%) and 12 priority medicines for children ranged from 28% to 57% (median 50%; IQR 14%). Few facilities (<1%) had all nominated medicines available. There was higher availability of priority medicines for women in hospitals than in primary care facilities: range 32%–80% (median 61%) versus 20%–39% (median 23%) and for children’s medicines 31%–71% (median 58%) versus 27%–57% (median 48%). Availability was higher in public than private facilities: for women’s medicines, range 21%–41% (median 34%) versus 4%–36% (median 27%) and for children’s medicines 28%–58% (median 51%) versus 5%–58% (median 46%). Patterns were mixed for rural and urban location for the priority medicines for women, but similar for children’s medicines.ConclusionsThe survey results show unacceptably low availability of priority medicines for women and children in the eight countries. Governments should ensure the availability of medicines for mothers and children if they are to achieve the health sustainable development goals.



2005 ◽  
Vol 91 (7) ◽  
pp. 550-551 ◽  
Author(s):  
I Choonara


2008 ◽  
Vol 93 (10) ◽  
pp. 815-815 ◽  
Author(s):  
I. Choonara ◽  
H. Bauchner


2010 ◽  
Vol 32 (3) ◽  
pp. 386-393 ◽  
Author(s):  
Rajan Ragupathy ◽  
June Tordoff ◽  
Pauline Norris ◽  
David Reith






BMJ ◽  
1993 ◽  
Vol 307 (6907) ◽  
pp. 773-773 ◽  
Author(s):  
M L Kulkarni ◽  
C Sureshkumar ◽  
V Venkataramana


Sign in / Sign up

Export Citation Format

Share Document